Industry news, page-1718

2024 Freshness Index... Who needs to freshen up [their pipeline]?


Of interest
1. Abbvie - almost 50% of their revenues coming from products >15 years of age, 60% > 10 years of age. If only there was a potential blockbuster AML treatment they could use to bolster their Venclexta program with, and to replace the revenue gaps created by Humira's loss of exclusivity?
2. Sanofi - 13 products in their clinical pipeline for haematology and oncology indications
3. Merck & Co (MSD) - 40% of revenues from products > 10 years old - bisantrene would pose a fantastic opportunity for the lifecycle management of Keyruda when patents expire in 2028.
4. Bristol Myers Squibb - with almost 70% of revenues coming from products > 10 years of age, and key patent expiries for Revlimid (2025/6), Eliquis (2027-29) and Opdivo (2028), BMS require additional M&A activity to bolster their pipeline.

https://www.evaluate.com/thought-leadership/the-2024-freshness-index-who-needs-to-freshen-up/#:~:text=Evaluate's%202024%20Freshness%20Index%20looks,over%2Dthe%2Dcounter%20drugs.